What the FDA labels say about taking them together
Cyclosporine and potassium chloride
Potassium chloride's FDA label (Potassium Chloride) of January 9, 2026 names cyclosporine in its drug interactions section; cyclosporine's label does not name potassium chloride itself but warns about its class (potassium salts). The potassium chloride label: “Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk …”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the potassium chloride FDA label on DailyMed (effective July 14, 2025, Upsher-Smith Laboratories, LLC).
What does the cyclosporine label say about potassium chloride?
Cyclosporine's label does not name potassium chloride itself; it warns about its class (potassium salts):
Cyclosporine label, drug interactionsCaution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the potassium chloride label say about cyclosporine?
Potassium Chloride label (Baxter Healthcare Corporation, January 9, 2026), drug interactionsDrug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ).
Source: FDA drug label (Potassium Chloride, NDA019904), Baxter Healthcare Corporation, effective January 9, 2026 (SPL set 092ddee4-572d-4771-8d95-880cea01097e), via openFDA
Source: FDA drug label (KLOR-CON M), Upsher-Smith Laboratories, LLC, effective July 14, 2025 (SPL set b89910f6-4ff5-4a62-8269-696f7c10e4f6), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Potassium chloride | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $0.0828 per tablet 10 mEq tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once